TriPath Imaging Finds a Friend

TriPath Imaging is getting a financial boost from one of its founding technology and equity providers, Roche. The company--the merged result of three different cytology start-ups--needs the money to go up against the so-far only successful player in the automated cytology market, Cytyc, hoping to exploit a much broader platform of technologies.

Near-term, the clear winner in the automated cytology screening wars is Cytyc Corp. , which has blown away the market with its focused development effort and stellar sales and marketing performance. But TriPath Imaging Inc. , after stumbling a bit, is getting some financial help from a powerful ally—Roche . Roche has agreed to invest more than $40 million in TriPath, buying five million shares. Including the three million shares it already owns, Roche will have a 24% stake in the company. Ultimately, if it exercises additional options, it will own 34%.

TriPath will gain about $43 million in cash from the initial transaction, which it will use to expand its sales...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.